-+ 0.00%
-+ 0.00%
-+ 0.00%

ONCOLYTICS BIOTECH® REPORTS STRONG DURABILITY AND SURVIVAL DATA IN ANAL CANCER, POSITIONING PELAREOREP AS POTENTIAL BACKBONE IMMUNOTHERAPY ACROSS HPV-DRIVEN CANCERS

Reuters·10/27/2026 13:32:57

Please log in to view news